

TARO PHARMACEUTICALS NORTH AMERICA INC.

BALANCE SHEETS

	March 31, 2026	March 31, 2025
	U.S. Dollars	
	Unaudited	
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 11,679	\$ 5,140
Short-term bank deposits	-	-
Marketable securities	-	-
Other receivables and prepaid expenses:		
Prepaid expenses	-	-
Intercompany balances	-	-
Other	-	-
TOTAL Other receivables and prepaid expenses	-	-
TOTAL CURRENT ASSETS	11,679	5,140
LONG-TERM RECEIVABLES AND OTHER ASSETS	372,627,244	372,627,244
GOODWILL	-	-
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	-	-
TOTAL ASSETS	<u>\$ 372,638,923</u>	<u>\$ 372,632,384</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable:		
Trade payables	\$ -	\$ -
Other current liabilities:		
Intercompany balances	30,000	-
Accrued expenses	-	-
Other	-	-
TOTAL Other current liabilities	<u>30,000</u>	<u>-</u>
TOTAL CURRENT LIABILITIES	<u>30,000</u>	<u>-</u>
SHAREHOLDERS' EQUITY	<u>372,608,923</u>	<u>372,632,384</u>
	<u>\$ 372,638,923</u>	<u>\$ 372,632,384</u>

TARO PHARMACEUTICALS NORTH AMERICA INC.

STATEMENTS OF INCOME

	For the year Ended March 31, 2026	For the year Ended March 31, 2025
	U.S. Dollars	
	Unaudited	
Sales	\$ -	\$ -
Cost of sales	-	-
Gross profit	-	-
Research and development	-	-
Selling and marketing expenses	-	-
General and administrative expenses	23,647	22,652
Operating income	(23,647)	(22,652)
Financing income (expenses), net	185	-
Other income (expense)	-	-
Income before taxes on income	(23,461)	(22,652)
Taxes on income	-	-
Net income for the period before subsidiaries and dividend	(23,461)	(22,652)
Dividend income, net	-	-
Subsidiaries	-	-
Net income for the period	\$ (23,461)	\$ (22,652)

TARO PHARMACEUTICALS NORTH AMERICA INC.

Changes in Shareholders' Equity

U.S. Dollars

Unaudited

	Number of Shares	Share Capital	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Total Taro Shareholders' March 31, 2024	Noncontrolling Interest
Balance at March 31, 2021	3	3	3,511,728	-	369,150,819	372,662,550	-
Adjustment to Opening RE balance	-	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-	-
Comprehensive loss, net of tax	-	-	-	-	-	-	-
Net income	-	-	-	-	(825)	(12,229)	-
Balance at March 31, 2022	3	3	3,511,728	-	369,149,994	372,666,865	-
Adjustment to Opening RE balance	-	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-	-
Comprehensive income, net of tax	-	-	-	-	-	-	-
Net income	-	-	-	-	(6,689)	(6,689)	-
Balance at March 31, 2023	3	3	3,511,728	-	369,143,305	372,660,176	-
Adjustment to Opening RE balance	-	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-	-
Comprehensive income, net of tax	-	-	-	-	-	-	-
Net income	-	-	-	-	-	-	-
Balance at March 31, 2024	3	3	3,511,728	-	369,143,305	372,660,176	-
Adjustment to Opening RE balance	-	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-	-
Comprehensive income, net of tax	-	-	-	-	-	-	-
Net income	-	-	-	-	(22,652)	-	-
Balance at March 31, 2025	3	3	3,511,728	-	369,120,653	372,632,384	-
Adjustment to Opening RE balance	-	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-	-
Comprehensive income, net of tax	-	-	-	-	-	-	-
Net income	-	-	-	-	(23,461)	-	-
Balance at March 31, 2026	3	3	3,511,728	-	369,097,192	372,608,923.03	-